Company Of The Day: Johnson & Johnson

+9.52%
Upside
178
Market
195
Trefis
JNJ: Johnson & Johnson logo
JNJ
Johnson & Johnson

What?

Johnson & Johnson (NYSE:JNJ) reported a mixed Q4 with revenue of $24.8 billion falling short of $25.3 billion consensus estimate but its earnings of $2.13, on a per share and adjusted basis, were a cent above the consensus estimate of $2.12.

Why?

Relevant Articles
  1. Should You Buy Johnson & Johnson Stock At $177?
  2. Here’s Why Centene Stock Is A Better Bet Compared To This Pharmaceuticals Bellwether
  3. This Semiconductor Chip Company Is Likely To Offer Better Returns Over Johnson & Johnson Stock
  4. Does Johnson & Johnson Stock Have More Upside?
  5. Company Of The Day: Johnson & Johnson
  6. Here’s Why Humira Maker Is A Better Bet Compared To Johnson & Johnson Stock

Growth was driven by the stronger performance of the pharmaceuticals business, while its medical devices and consumer healthcare business faced headwinds due to the spread of the Omicron.

So What?

JNJ stock rose by about 3% in Tuesday’s trading. We estimate Johnson & Johnson valuation at $202 per share, about 20% ahead of the current market price. This represents a forward P/EBITDA multiple of 19.1 for the company based on our forecast for Johnson & Johnson EBITDA.

See Our Complete Analysis For Johnson & Johnson

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

Returns Jan 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 JNJ Return -2% -2% 45%
 S&P 500 Return -9% -9% 95%
 Trefis MS Portfolio Return -13% -13% 243%

[1] Month-to-date and year-to-date as of 1/26/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates